Merck & Co., Inc. (MRK.PA)
Paris - Paris Delayed price. Currency in EUR
Add to watchlist
As of 05:35PM CEST. Market open.
Loading interactive chart…
- Simply Wall St.
Merck First Quarter 2024 Earnings: Beats Expectations
Merck ( NYSE:MRK ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8b (up 8.9% from 1Q 2023). Net...
- Business Wire
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
- Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
© 2024 Yahoo. All rights reserved.